Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is a single center phase 1 trial to observe safety and efficacy of metronomic
capecitabine plus PD-L1 antibody camrelizumab to treat hepatobiliary, pancreatic and other
gastrointestinal carcinoma (non-stomach, non-esophagi) patients who had disease progression
after all standard regimens.
This study is one of the cohorts of a multi-cohort trial called Combination of Metronomic
capecitabine with Camrelizumab for treatment of refractory solid tumor (McCrest) trial.